{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T17:59:41Z","timestamp":1775152781094,"version":"3.50.1"},"reference-count":104,"publisher":"Informa UK Limited","issue":"31","funder":[{"name":"Novartis"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.2217\/fon-2023-0274","type":"journal-article","created":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T11:05:42Z","timestamp":1698318342000},"page":"2083-2101","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":4,"title":["Mosunetuzumab and the Emerging Role of T-Cell-Engaging Therapy in Follicular Lymphoma"],"prefix":"10.1080","volume":"19","author":[{"given":"Sarah","family":"Matarasso","sequence":"first","affiliation":[{"name":"Lady Davis Institute, Jewish General Hospital,McGill University,\r3755 Cote Ste Catherine, E725, \rMontreal, \rQC, H3T 1E2, \rCanada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarit","family":"Assouline","sequence":"additional","affiliation":[{"name":"Lady Davis Institute, Jewish General Hospital,McGill University,\r3755 Cote Ste Catherine, E725, \rMontreal, \rQC, H3T 1E2, \rCanada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2023,10,26]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.94"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21357"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01535-y"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01048-6"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00400"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.7534"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.08.005"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15149"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00340-z"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00010"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30441-1"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314583"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01622-0"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.12.3793"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00591-X"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00335-7"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00931"},{"key":"e_1_3_5_20_1","unstructured":"European Medicines Agency . Lunsumio (2022). www.ema.europa.eu\/en\/medicines\/human\/EPAR\/lunsumio"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/d41591-023-00010-0"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.3.1110"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004588"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2005.08.010"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-156790"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614598"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00605"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01073"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-217687"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805104"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.0001"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30097-3"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.3656"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.223"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.03.022"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31374"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.07.028"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.008"},{"key":"e_1_3_5_39_1","unstructured":"National Comprehensive Cancer Network . B-cell lymphomas (version 2.2023) (2023). www.nccn.org\/professionals\/physician_gls\/pdf\/b-cell.pdf"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2004.n.015"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.076"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.6400"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.2015"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30441-1"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25711"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.4648"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2009.11.002"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2014.5756"},{"key":"e_1_3_5_49_1","unstructured":"Acrotech Biopharma LLC . Zevalin FDA prescribing information. https:\/\/zevalin.com\/wp-content\/uploads\/2019\/04\/PI-ZEVALIN-092019.pdf"},{"key":"e_1_3_5_50_1","unstructured":"European Medicines Agency . Zevalin Product Information. www.ema.europa.eu\/en\/documents\/product-information\/zevalin-epar-product-information_en.pdf"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15712"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06841.x"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-158631"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS7568"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.8853"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-804641"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.7510"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006083"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2011.01.001"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc839"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature08638"},{"key":"e_1_3_5_62_1","unstructured":"US Food and Drug Administration . FDA Introductory Comments: Oncologic Drugs Advisory Committee Meeting 21 April 2022 (2022). www.fda.gov\/media\/157837\/download"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03433"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-538546"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00915"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.281266"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-147564"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-115670"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.7550"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2013.04.011"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002773"},{"key":"e_1_3_5_72_1","unstructured":"US Food and Drug Administration . Tazemetostat prescribing information. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/213400s000lbl.pdf"},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2591"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.1038\/314628a0"},{"key":"e_1_3_5_75_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0356-3"},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00889-8"},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-136044"},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03175"},{"key":"e_1_3_5_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00072-2"},{"key":"e_1_3_5_80_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa4802"},{"key":"e_1_3_5_81_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-123933"},{"key":"e_1_3_5_82_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.7526"},{"key":"e_1_3_5_83_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-147937"},{"key":"e_1_3_5_84_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.7518"},{"key":"e_1_3_5_85_1","volume-title":"64th American Society of Hematology Annual Meeting and Exposition.","author":"Budde EL","year":"2022","unstructured":"Budde EL , BartlettNL, GiriPet al. Subcutaneous mosunetuzumab is active with a manageable safety profile in patients (pts) with relapsed\/refractory (R\/R) B-cell non-Hodgkin Lymphomas (B-NHLs): updated results from a phase I\/II study. Presented at: 64th American Society of Hematology Annual Meeting and Exposition.New Orleans, LA, USA, 10 December 2022."},{"key":"e_1_3_5_86_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-135818"},{"key":"e_1_3_5_87_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-157691"},{"key":"e_1_3_5_88_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000847372.57687.d4"},{"key":"e_1_3_5_89_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.7.2217.419k02_2217_2224"},{"key":"e_1_3_5_90_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI119110"},{"key":"e_1_3_5_91_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"e_1_3_5_92_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-798322"},{"key":"e_1_3_5_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"e_1_3_5_94_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0036-4"},{"key":"e_1_3_5_95_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2022.2039432"},{"key":"e_1_3_5_96_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609783"},{"key":"e_1_3_5_97_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-3497-0"},{"key":"e_1_3_5_98_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0698"},{"key":"e_1_3_5_99_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-1319"},{"key":"e_1_3_5_100_1","unstructured":"US Food and Drug Administration . Orphan drug designations and approvals \u2013 mosunetuzumab. www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/detailedIndex.cfm?cfgridkey=663418"},{"key":"e_1_3_5_101_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS7588"},{"key":"e_1_3_5_102_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-145694"},{"key":"e_1_3_5_103_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008097"},{"key":"e_1_3_5_104_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.3696"},{"key":"e_1_3_5_105_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02035"},{"key":"e_1_3_5_106_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.08.006"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2023-0274","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:45:03Z","timestamp":1719125103000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2023-0274"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":104,"journal-issue":{"issue":"31","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.2217\/fon-2023-0274"],"URL":"https:\/\/doi.org\/10.2217\/fon-2023-0274","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-03-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}